MIT professor Andrew Lo (Credit: J.T. MacMillan Photography at Endpoints #BIO22)
July 18, 2022 11:27 AM EDTUpdated 01:47 PM
Deals
Bioregnum

Black­Rock joins An­drew Lo's risk analy­sis firm to search for odds-on biotech bets in tur­bu­lent times

MIT fi­nance pro­fes­sor An­drew Lo has more in­sid­er con­nec­tions than just about any oth­er aca­d­e­m­ic play­er you’ll find in any in­dus­try. And to­day, if you …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Louisiana's Bill Cas­sidy named next chair of Sen­ate health com­mit­tee

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times